Weill Cornell Medicine
1300 York Ave
5 articles with Weill Cornell Medicine
Study Identifies the Molecular Mechanisms by which Noonan Syndrome RAF1 mutations cause Cardiac Hypertrophy
Investigators from the Masonic Medical Research Institute, Weill Cornell Medicine and Beth Israel Deaconess Medical Center have identified the molecular mechanisms by which RAF1 mutations in patients with Noonan Syndrome cause hypertrophic cardiomyopathy, a dangerous thickening of the heart muscle that can lead to heart failure and death.
Consuming the equivalent of one can of soda per day caused mice predisposed to colon cancer to develop larger tumors, according to a study by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Gotham Therapeutics launched in New York with a $54 million Series A financing. The focus is on a subgroup of RNA metabolism called epitranscriptomics. This involves the biochemical modifications of RNA within a cell, which have an impact on gene expression.
July 13 Research Roundup: Gene Therapy for Cholesterol, Beta-Thalassemia, and Kidney Disease, and...
7/13/2018There are plenty of great scientific research stories out this week. Here’s a look at just a few of them from gene therapy for cholesterol to kidney disease and more.
TriNetX is a network comprised of healthcare organizations representing nearly 100 million patients globally, biopharmaceutical companies, and CROs.